ArticleBMJ open2025
Association of ceramide risk scores with rheumatoid arthritis: a FINRISK population-based cohort study.
Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Ceramide in Type 2 Diabetes and Obesity: Modulation by Nutrients and Dietary Patterns and Opportunities to Prevent and/or Manage Metabolic-Related Conditions.Metabolites · 2026Review
- [Determination of 30 homologues of phosphatidylcholines and lysophosphatidylcholines in human serum by liquid chromatography-tandem mass spectrometry and their correlation analysis with coronary artery disease].Se pu = Chinese journal of chromatography · 2026Article
- Plasma metabolomic and lipidomic signatures characteristic of treatment non-response in rheumatoid arthritis.Frontiers in immunology · 2026Article
- Exploring the association between ceramide, phosphatidylcholine, and COPD prevalence and incidence: a FINRISK population-based cohort study.BMC pulmonary medicine · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to explore the association between lipid-based Cardiovascular Event Risk Tests (CERT1 and CERT2), including ceramides (Cer) and phosphatidylcholine (PC) lipid species, and rheumatoid arthritis (RA), an inflammatory disease that can increase the risk of cardiovascular diseases.
designProspective population-based cohort study.
settingPrimary care centres across five geographical areas in Finland.
methodsThe study included 7702 individuals (selected from the FINRISK cohort) who were assessed for the prevalence and incidence of RA. At baseline, the cohort included 7518 RA-free individuals, among whom 329 developed RA during the study, and 184 had a history of RA at baseline. Serum levels of ceramides and PC were measured using mass spectrometry, and CERT scores were calculated.
main outcome measuresPrevalence and incidence of RA, CERT scores, and serum lipid levels.
resultsCERT scores were associated with prevalent RA but not with incident RA in the full cohort. Adjusted ORs and 95% CI for prevalent RA were 1.24 (95% CI 1.05 to 1.46) for CERT1 and 1.42 (95% CI 1.20 to 1.68) for CERT2. Stratified analyses showed that these associations were consistent among individuals over 50 years of age and across both sexes. The Cer (d18:1/16:0)/PC (16:0/22:5) ratio was significantly associated with RA in younger individuals (OR 1.66; 95% CI (1.26 to 2.18)). Overall, the association between lipids and RA was stronger in women than men.
conclusionsThe study shows a significant association between prevalent RA and bioactive lipid species used for cardiovascular risk assessment. These findings emphasise the importance of considering residual inflammatory risks, such as RA, in cardiovascular risk evaluations in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.